|
|
||||||||
1 Depts of Respiratory Medicine, and 2 Physiotherapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
CORRESPONDENCE: H. Matsumoto, Dept of Respiratory Medicine, Postgraduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan. Fax: 81 757514643. E-mail: hmatsumo{at}kuhp.kyoto-u.ac.jp
Keywords: Airway inflammation, asthma, high-sensitivity C-reactive protein, induced sputum
Received: October 2, 2005
Accepted November 25, 2005
Asthma is characterised by chronic inflammation of the airways, but the relevance of high-sensitivity assays for C-reactive protein (hs-CRP), which are known to be a sensitive marker of low-grade systemic inflammation, has not been fully studied in asthma. The objective was to examine serum hs-CRP levels in patients with asthma and their relationship to clinical characteristics and degree of airway inflammation.
Serum hs-CRP levels were cross-sectionally examined in steroid-naive (n = 22) and steroid-inhaling (n = 23) adult patients with asthma and healthy controls (n = 14). All were nonsmokers.
Serum hs-CRP levels were significantly increased in steroid-naive patients (mean±SD 1.33±1.48 mg·L1) compared with controls (0.21±0.30 mg·L1), but not in patients on inhaled corticosteroid. Among steroid-naive patients, serum hs-CRP levels significantly negatively correlated with indices of pulmonary function (forced expiratory volume in one second/forced vital capacity and forced mid-expiratory flow) and positively with sputum eosinophil count. Among patients on inhaled corticosteroid, hs-CRP levels did not correlate with any indices.
In conclusion, an increase in serum C-reactive protein levels measured by high-sensitivity assays may be associated with airflow obstruction and airway inflammation, and may serve as a surrogate marker of airway inflammation in asthma.
This article has been cited by other articles:
![]() |
J B Morjaria, A J Chauhan, K S Babu, R Polosa, D E Davies, and S T Holgate The role of a soluble TNF{alpha} receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial Thorax, July 1, 2008; 63(7): 584 - 591. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Allayee, J. Hartiala, W. Lee, M. Mehrabian, C. G. Irvin, D. V. Conti, and J. J. Lima The Effect of Montelukast and Low-Dose Theophylline on Cardiovascular Disease Risk Factors in Asthmatics Chest, September 1, 2007; 132(3): 868 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Anderson COPD, asthma and C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 874 - 876. [Full Text] [PDF] |
||||
![]() |
E. F. M. Wouters The systemic face of airway diseases: the role of C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 877 - 879. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |